Skip to main content
Search...

Takeda

Tokyo-headquartered Takeda is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company traces its origins back to 1781. 

Today, Takeda focuses on four therapeutic areas: oncology, rare genetics and haematology, neuroscience, and gastroenterology. It also makes targeted R&D investments in plasma-derived therapies and vaccines. 
 

Over 25 years on Irish soil

Takeda celebrated 25 years of business in Ireland in 2022. Since first establishing its manufacturing facility at Bray, County Wicklow in 1997, the company has set up three other locations in Ireland at Baggot Street, Citywest and Grange Castle in Dublin, providing medicines to patients in more than 60 international markets. 

Together, Takeda’s sites in Ireland employ more than 900 people in a variety of roles including commercial operations, manufacturing, supply chain, quality, and corporate services 
 

A first in Ireland

The company has continued to expand its Irish operations. In 2022, it opened a cell therapy production facility at its Grange Castle site, said to be the first of its kind in Ireland. The company said the site will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients. There are over 100 people currently working at the cell therapy facility with another 100 new jobs expected to be filled.
 

How Ireland Helps Takeda

  • Takeda set up its first Irish operation in 1997
  • More than 900 people are now employed across three sites in Ireland
  • Takeda’s Irish operations continue to grow; a new cell therapy facility opened in 2022
  • More than 60 international markets served from Ireland

More than 900 people are now employed across three sites in Ireland
More than 900 people are now employed across three sites in Ireland
Open Quote

The Grange Castle site is growing from strength to strength thanks to a great team and strong investment in our people and technology. The treatment produced here will be delivered to patients within 72 hours of being released from Grange Castle which means we are closer to the patient than we have ever been and this brings a great sense of pride to our team.

Paul Keogh,
Grange Castle Site Head, Takeda
Close Quote